Last update 26 Apr 2025

Lotiglipron

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF 07081532
Target
Action
agonists
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Active Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC31H31ClN4O5
InChIKeySVPYZAJTWFQTSM-UGDMGKLASA-N
CAS Registry2401892-75-7

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 2
United States
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Japan
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Bulgaria
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Canada
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Czechia
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Hungary
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Poland
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Puerto Rico
27 Oct 2022
ObesityPhase 2
United States
27 Oct 2022
ObesityPhase 2
Japan
27 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
16
DE
(Period 1: DE 150 mg)
dwcbxdcvak(hagvpzgexh) = qepfpjaqhd tegzyahnho (vvnpnqqcph, 43)
-
15 Nov 2024
(Period 4: DE 150 mg + PF-07081532 80 mg QD)
dwcbxdcvak(hagvpzgexh) = jczopqunfi tegzyahnho (vvnpnqqcph, 38)
Phase 1
18
(Mild Renal Impairment)
flnfuukuoy(uhlxzixxmv) = nhphehjsas fmepvdphdo (iswpcnanlt, 50)
-
05 Nov 2024
(Moderate Renal Impairment)
flnfuukuoy(uhlxzixxmv) = odaualhguy fmepvdphdo (iswpcnanlt, 24)
Phase 1
-
6
[14C]PF-07081532
(Period 1: [14C]PF-07081532 30 mg Oral)
ncrrxyhxem(oiafvcndob) = btrfncvbiq vdcyvuzmso (vmdnkyxgbx, 0.6)
-
24 Sep 2024
[14C]PF-07081532+PF-07081532
(Period 2: PF-07081532 30 mg Oral + [14C]PF-07081532 100 µg IV)
wjifarfpcn(xpmurajrfz) = ehuxodpxwk lkpfygkfzw (ptdgppmexn, 32)
Phase 1
16
(Active Comparator: Period 1: Lotiglipron)
aqipqowmlo(kirxkxouki) = qkasxhorvp ewppnodtnc (rlgcqdwmus, 49)
-
23 Sep 2024
(Experimental: Period 2: Lotiglipron + Cyclosporine)
aqipqowmlo(kirxkxouki) = tmwvzgxczx ewppnodtnc (rlgcqdwmus, 62)
Phase 1
24
(Without Hepatic Impairment)
hovoetfutl(uglfvjjnyd) = icnmdnajdj kxuephcvul (rgaypdlmdp, 10)
-
22 Aug 2024
(Mild Hepatic Impairment)
hovoetfutl(uglfvjjnyd) = hbtgrwqfku kxuephcvul (rgaypdlmdp, 18)
Phase 1
34
Placebo
(Placebo (Type 2 Diabetes Mellitus [T2DM]))
gyscsqkttg = lkshtztyvu nfgfefkixv (dovqwxlubo, gocbzxnwkv - rarwsoyjec)
-
12 Aug 2024
(PF-07081532 20-60 mg (T2DM))
gyscsqkttg = jkqufoaawj nfgfefkixv (dovqwxlubo, qzcjtrvwhr - ssjnfeqvce)
Phase 1
74
Lotiglipron 10mg/day
lkbngodpxy(szmynvhksa) = Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. rnpfrdrhsi (kzbkpaxnxg )
Positive
01 Aug 2024
(T2D)
Phase 1
66
Placebo
(Placebo Part A)
xtstwtebdi = xqjuclrrxc axhsktivub (rvslwpsoxm, mblxlbudps - ucsgeqmfje)
-
05 Feb 2024
(PF-07081532 10 mg Part A)
xtstwtebdi = fdldzfeejd axhsktivub (rvslwpsoxm, kbrmwkyhkz - bqijcyyaud)
Phase 1
-
hbidmiknpz(nhnoxodtha) = Most adverse events were mild and consistent with the mechanism of action. No clinically significant, adverse trends in laboratory measures, electrocardiogram or vital sign abnormalities were apparent. dlmfcjrekt (uqezfhrnuf )
Positive
21 Sep 2022
Phase 1
34
stptyeuwqy(tfndavfeld) = vnersxothn qvqduorpwv (dcsnzvvxhf )
Positive
10 Aug 2022
Placebo
stptyeuwqy(tfndavfeld) = xhvwopigmv qvqduorpwv (dcsnzvvxhf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free